Current clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients

Area of Science:

• Nephrology
• Biochemistry
• Rheumatology

Background:

• Beta2-microglobulin (beta2-m) amyloidosis is an increasing complication in patients undergoing long-term hemodialysis.
• The prevalence of beta2-m amyloid-related osteoarthropathy and carpal tunnel syndrome rises with the duration of dialysis treatment.

Purpose of the Study:

• To investigate the factors influencing beta2-microglobulin (beta2-m) amyloid fibril formation.
• To evaluate the effectiveness of current dialysis techniques in managing beta2-m amyloidosis.

Main Methods:

• Utilized an in vitro model to study beta2-m amyloid fibril extension.
• Analyzed the impact of amyloid-associated molecules like apolipoprotein E and proteoglycans on fibril formation.
• Reviewed therapeutic approaches including dialysis techniques for beta2-m removal.

Main Results:

• Retention of beta2-m is necessary but not sufficient for amyloidosis onset.
• Molecules such as apolipoprotein E and proteoglycans accelerate beta2-m amyloid fibril formation in vitro.
• Current dialysis methods (high-flux membranes, adsorption columns) for beta2-m removal lack proven efficacy in reducing amyloid deposits.

Conclusions:

• Beta2-microglobulin amyloidosis is a progressive complication in long-term hemodialysis patients.
• Co-factors like apolipoprotein E and proteoglycans play a role in accelerating amyloid formation.
• More effective treatments are required as current dialysis strategies for beta2-m removal have not demonstrated a reduction in amyloid deposits.